APAC High Content Screening Market - Industry Trends and Forecast to 2030
The Asia-Pacific high content screening market is expected to reach USD 874,587.24 thousand by 2030 from USD 459,657.52 thousand in 2022, growing at a CAGR of 8.4% during the forecast period of 2023 to 2030.
Market SegmentationAsia-Pacific high content screening Market, By Product Type (Instruments, Consumables, Software, Services, and Accessories), Application (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling, and Other Applications), Technology (Microscopy, Flow Cytometry, Mass Spectrometry, Western Blotting, ELISA, Immunohistochemistry, and Others), End User (Pharmaceutical and Biotechnology Companies, Academic and Government Institutes, Contract Research Organizations, Laboratories, and Others), Distribution Channel (Direct Tenders and Retail Sales), Country (Japan, China, India, South Korea, Australia, New Zealand, Singapore, Thailand, Malaysia, Vietnam, Taiwan, Indonesia, Philippines and Rest of Asia-Pacific) - Industry Trends and Forecast to 2030
Overview of Asia-Pacific High Content Screening Market DynamicsDriver
• Increasing drug discovery and development activities
Restraint
• High cost associated with initial setup and maintenance
Opportunity
• The growing number of Contract Research Organizations (CROs) providing HCS services
Market PlayersSome of the major market players operating in the Asia-Pacific high content screening market are:• BD
• Merck KGaA
• Corning Incorporated
• Carl Zeiss AG
• Sartorius AG
• EVIDENT
• Molecular Devices, LLC. (Subsidiary of Danaher Corporation)
• Thermo Fisher Scientific Inc.
• PerkinElmer Inc.
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Yokogawa Electric Corporation
• Sysmex Corporation
• Genedata AG
• Miltenyi Biotec